Domača stranBMY • NYSE
add
Bristol-Myers Squibb Co
58,87 $
Po zaprtju:(0,068 %)−0,040
58,83 $
Konec trgovanja: 22. nov., 17:19:06 GMT -5 · USD · NYSE · Izjava
Prejšnji trg. dan.
58,23 $
Dnevni razpon
57,62 $ - 58,92 $
Letni razpon
39,35 $ - 61,08 $
Tržna kapitalizacija
119,40 mrd. USD
Povprečni obseg
10,65 mio.
Razm. P/E
-
Dividendna donosnost
4,08 %
Primarna borza
NYSE
V novicah
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (USD) | sep. 2024info | Sprememba L/L |
|---|---|---|
Prihodek | 11,89 mrd. | 8,44 % |
Stroški poslovanja | 6,84 mrd. | 7,33 % |
Čisti dohodek | 1,21 mrd. | −37,19 % |
Čista dobičkovnost prihodkov | 10,18 | −42,09 % |
Earnings per share | 1,80 | −10,00 % |
EBITDA | 4,83 mrd. | 5,53 % |
Efektivna davčna stopnja | 27,51 % | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (USD) | sep. 2024info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 8,09 mrd. | 5,32 % |
Skupna sredstva | 93,67 mrd. | 2,64 % |
Skupne obveznosti | 76,47 mrd. | 22,94 % |
Celoten lastniški kapital | 17,20 mrd. | — |
Shares outstanding | 2,03 mrd. | — |
Razmerje P/B | 6,89 | — |
Donosnost sredstev | 5,83 % | — |
Donosnost kapitala | 7,86 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (USD) | sep. 2024info | Sprememba L/L |
|---|---|---|
Čisti dohodek | 1,21 mrd. | −37,19 % |
Denar iz dejavnosti | 5,59 mrd. | 17,68 % |
Denar iz naložb | −219,00 mio. | 46,59 % |
Denar iz financiranja | −3,85 mrd. | 25,35 % |
Neto sprememba denarnih sredstev | 1,60 mrd. | 286,35 % |
Prost denarni tok | 5,59 mrd. | 51,71 % |
Vizitka
The Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company. Headquartered in Princeton, New Jersey, BMS is one of the world's largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations. For fiscal 2022, it had a total revenue of $46.2 billion.
Bristol Myers Squibb manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis, and psychiatric disorders.
BMS's primary research and development sites are located in Lawrence, New Jersey, Summit, New Jersey, formerly HQ of Celgene, New Brunswick, New Jersey, Redwood City, California, and Seville in Spain, with other sites in Devens and Cambridge, Massachusetts, Braine-l'Alleud, Belgium, Tokyo, Japan, Hyderabad; Bangalore, India and Wirral, United Kingdom. BMS previously had an R&D site in Wallingford, Connecticut. Wikipedia
Generalni direktor
Datum ustanovitve
1887
Sedež organizacije
Spletno mesto
Zaposleni
34.100
